RH
Therapeutic Areas
Cyted Health Pipeline
| Drug | Indication | Phase |
|---|---|---|
| EndoSign® for Barrett's Esophagus / Esophageal Neoplasia | Detection and risk stratification of Barrett's Esophagus and early esophageal neoplasia | Commercial |
| BEST4 Screening Trial | Large-scale randomized controlled trial for population screening of Barrett's Esophagus | Clinical Trial |
| Cytoprime2 Community Care Study | Effectiveness of EndoSign® in community care settings for early esophageal cancer detection | Clinical Trial |
Leadership Team at Cyted Health
MG
Marcel Gehrung, PhD
Co-founder & Chief Executive Officer
PR
Prof. Rebecca Fitzgerald, FMedSci OBE
Co-founder & Clinical Advisor
BH
Betsy Hanna
President & US General Manager
DM
Dr. Maria O’Donovan, MB BCH, MD, FRCPath
Co-founder & Lead Pathologist